

18 February 2021

March 2021 Pharmaceutical Schedule Dispatch

This dispatch email is provided to pharmacists as an early notification of the changes to be announced in the **March 2021** Update to the Pharmaceutical Schedule.

New listings

- Aqueous cream (Topiderm) crm, 500 g (p'code 2604108)
- Clozapine (Versacloz) suspension 50 mg per ml, 100 ml – Hospital pharmacy [HP4] and safety medicine; prescriber may determine dispensing frequency (p'code 2604965)
- Diabetic enteral feed 1kcal/ml (Glucerna Select) liquid, 500 ml OP – Special Authority – Hospital pharmacy [HP3] (p'code 2605651)
- Fat modified feed (Monogen) powder, 400 g OP – Special Authority – Hospital pharmacy [HP3] (p'code 2601443) – new Pharmacode listing
- Influenza vaccine (Afluria Quad Junior (2021 Formulation)) inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) – Xpharm and access criteria apply (p'code 2602733)
- Influenza vaccine (Afluria Quad (2021 Formulation)) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) – only on a prescription, no patient co-payment payable and access criteria apply (p'code 2602725)
- Influenza vaccine (Fluad Quad (2021 Formulation)) inj 60 mcg in 0.5 ml syringe (adjuvanted quadrivalent vaccine) – only on a prescription, no patient co-payment payable and access criteria apply (p'code 2602741)
- Ivacaftor (Kalydeco) tab 150 mg (p'code 2586118), oral granules 50 mg, sachet (p'code 2586134) and oral granules 75 mg, sachet (p'code 2586126) – PCT only – Specialist – Special Authority
- Low calcium infant formula (Locasol) powder, 400 g OP – Special Authority – Hospital pharmacy [HP3] (p'code 2601451) – new Pharmacode listing
- Mifepristone (Mifegyne) tab 200 mg, 1 tab pack – up to 15 tab available on a PSO and only on a PSO (p'code 2603004)
- Nitrofurantoin (Macrobid) cap modified-release 100 mg – wastage claimable (p'code 2493624)
- Oestradiol (Estradiol TDP Mylan) patch 75 mcg per day – no more than 2 patch per week, only on a prescription, S29 and wastage claimable (p'code 2605317)
- Omeprazole cap 10 mg (Omeprazole actavis 10) (p'code 2604930), cap 20 mg (Omeprazole actavis 20) (p'code 2604949) and cap 40 mg (Omeprazole actavis 40) (p'code 2604957) – new Pharmacode listing
- Oxycodone hydrochloride (Oxycodone Sandoz S29) tab controlled-release 5 mg, 28 tab pack – only on a controlled drug form, no patient co-payment payable, safety medicine; prescriber may determine dispensing frequency, S29 and wastage claimable (p'code 2605643)

- Paroxetine (Paxtine) tab 20 mg (p'code 2600188)
- Pharmacy services (BSF Ambrisentan Mylan) brand switch fee – may only be claimed once per patient (p'code 2605309)
- Phenoxymethylpenicillin (penicillin V) (Cilicaine VK) cap 500 mg – up to 20 cap available on a PSO and up to 2 x the maximum PSO quantity for RFPP (p'code 2602873) – new Pharmacode listing
- Primaquine (Sanofi Primaquine) tab 15 mg – Special Authority – Retail pharmacy, S29 and wastage claimable (p'code 2587637)
- Terbinafine (Deolate) tab 250 mg, 84 tab pack (p'code 2597160)
- Warfarin sodium (Coumadin) tab 5 mg (p'code 2586983) – new Pharmacode listing

Changes to restrictions, chemical names and presentations

- Acitretin (Novatretin) cap 10 mg and 25 mg – amended Special Authority criteria
- Ambrisentan (Ambrisentan Mylan) tab 5 mg and 10 mg – addition of brand switch fee
- Atomoxetine (Generic Partners) cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg – brand switch fee removed
- Bromocriptine mesylate (Apo-Bromocriptine) tab 2.5 mg – addition of Subsidy by endorsement
- Dimethyl fumarate (Tecfidera) cap 120 mg and 240 mg – amended Special Authority criteria and addition of note
- Empagliflozin (Jardiance) tab 10 mg and 25 mg – amended Special Authority criteria
- Empagliflozin with metformin hydrochloride (Jardiamet) tab 5 mg with 500 mg and 1,000 mg metformin hydrochloride and tab 12.5 mg with 500 mg and 1,000 mg metformin hydrochloride – amended Special Authority criteria
- Fingolimod (Gilenya) cap 0.5 mg – amended Special Authority criteria and addition of note
- Glatiramer acetate (Copaxone) inj 40 mg prefilled syringe – amended Special Authority criteria and addition of note
- Interferon beta-1-alpha inj 6 million iu prefilled syringe (Avonex) and injection 6 million iu per 0.5 ml pen injector (Avonex Pen) – amended Special Authority criteria and addition of note
- Interferon beta-1-beta (Betaferon) inj 8 million iu per 1 ml – amended Special Authority criteria and addition of note
- Isotretinoin (Oratane) cap 5 mg, 10 mg and 20 mg – amended Special Authority criteria
- Moclobemide (Aurorix) tab 300 mg – reinstate stat dispensing
- Multiple sclerosis treatments – amended Special Authority criteria
- Natalizumab (Tysabri) inj 20 mg per ml, 15 ml vial – amended Special Authority criteria and addition of note
- Ocrelizumab (Ocrevus) inj 30 mg per ml, 10 ml vial – amended Special Authority criteria and addition of note

- Propranolol (Roxane-Propranolol) oral liq 4 mg per ml, 500 ml – amended brand name
- Rituximab inj 100 mg per 10 ml vial and 500 mg per 50 ml vial (Riximyo) and inj 1 mg for ECP (Baxter (Riximyo)) – amended Special Authority criteria
- Teriflunomide (Aubagio) tab 14 mg – amended Special Authority criteria and addition of note
- Timolol (Apo-Timol) tab 10 mg – addition of Subsidy by endorsement

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Clotrimazole	Crn 1%, 20 g OP	Clomazol
Glycopyrronium bromide	Inj 200 mcg per ml, 1 ml ampoule	Max Health
Glyceryl trinitrate	Oral pump spray, 400 mcg per dose, 250 dose OP	Nitrolingual Pump Spray

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Teriflunomide	Tab 14 mg	Aubagio	

Stopping the printed Schedules and Updates

We're stopping printing the Schedule but it will continue to be available online. The April edition of the Community Pharmaceutical Schedule will be the final printed and posted books or Updates. More information can be found at pharmac.govt.nz/movingonline